Innate Pharma S.A. (IPH.PA)
| Previous close | 2.2050 |
| Open | 2.2450 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.2150 - 2.2600 |
| 52-week range | 2.1100 - 3.3450 |
| Volume | |
| Avg. volume | 60,809 |
| Market cap | 181.49M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings date | 10 May 2024 - 18 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.60 |
Business WireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
Business WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024
ZacksAll You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
